A case of anti‐SAE1/2 antibody–positive dermatomyositis with extensive panniculitis: A possible cutaneous manifestation of treatment resistance

• Published in: Journal of dermatology 2024-02, Vol.51 (2), p.301-306
• Main Authors: Fujisaki, Misako, Kasamatsu, Hiroshi, Nishimura, Kentarou, Yoshida, Yasuyuki, Muneishi, Yoriko, Yamaguchi, Tomohisa, Nishino, Ichizo, Konishi, Risa, Ichimura, Yuki, Okiyama, Naoko, Oyama, Noritaka, Hasegawa, Minoru
• Format: Article
• Language: English
• Subjects: anti‐SAE antibody; Autoantibodies; Case reports; Dermatomyositis; Dysphagia; Erythema; Immunoglobulin G; immunosuppressive agents; Inflammation; Malignancy; Melanoma; Mycophenolate mofetil; Mycophenolic acid; Myositis; panniculitis; Patients; Remission; Skin diseases; Steroids; Tacrolimus; Treatment resistance; Ubiquitin
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.17000

Dermatomyositis constitutes a heterogeneous group of autoimmune inflammatory conditions with a wide variety of clinical outcomes. The symptomatic heterogeneity carries skin, muscle, and joint manifestations; pulmonary and cardiac involvements; and concomitant malignancy. Any of these symptoms often appear at different combinations and time courses, thus posing difficulty in early diagnosis and appropriate treatment choice. Recent progress in laboratory investigations explored the identification of several myositis‐specific autoantibodies (MSAs) and myositis‐associated autoantibodies, allowing precise characterization for a clinical perspective of the disease. MSAs can be detectable in approximately 80% of patients with whole dermatomyositis, some of which closely reflect unique clinical features in the particular disease subset(s), including the distribution and severity of organ involvement, treatment response, and prognosis. However, only limited evidence has been available in dermatomyositis‐associated panniculitis, mostly that in anti‐ melanoma differentiation‐associated protein 5 antibody–positive disease. We present a rare case of a patients with dermatomyositis with extensive panniculitis on the trunk whose serum IgG autoantibodies reacted with both subunits of small ubiquitin‐like modifier activating enzymes (SAEs), SAE1 and SAE2. The onset of panniculitis coincided with increased disease activity, including disease‐related skin manifestations, fever, dysphagia, and muscle weakness in the extremities. These symptoms responded well to a high dose of systemic steroid, but even upon receiving a high‐dose intravenous immunoglobulin, the panniculitic lesions and pruritic erythema flared with tapering of steroid dose, further requiring tacrolimus and mycophenolate mofetil to achieve disease remission. To our knowledge, this is the third reported case of anti‐SAE autoantibody–positive dermatomyositis with panniculitis. We aim to extend the understanding of the current limitation and further perspective in the clinical management of the extremely rare skin manifestation associated with dermatomyositis.